LP003(Lintonpharm)

N/A

Report date: 2026/03/19 17:03:31

Base Information

Drug NameLP003(Lintonpharm)
Drug Alias NameLP003(Lintonpharm)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-GD2
TargetsT cell surface glycoprotein CD3Disialoganglioside GD2
Therapy Area/IndicationsSmall Cell Lung CarcinomaNeuroblastomaSarcoma, Ewing +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangzhou Lintonpharm Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Lintonpharm Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaNeuroblastomaSarcoma, Ewing +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A